Answers are grounded in this paper and cite their sources.
In Japan, the Act on Safety of Regenerative Medicine regulates unapproved regenerative medicine. Other nations market regenerative medicine products, bypassing regulatory approval. To identify unapproved orthopedic regenerative medicine, we have used data based on the Act. Platelet-rich plasma was often used. The common target was the knee. Prices averaged $2,490.
No takes yet. Share an insight, caveat, or question.
Ukon et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: